Barclays downgraded Centene (CNC) to Equal Weight from Overweight with a price target of $65, down from $84. Following Q1 earnings and “several negative data points” around Part D mix, Affordable Care Act trend, and preliminary 2026 ACA rates, the firm is more concerned on the Medicare Part D and individual ACA businesses, which it believes carry negative earnings risk for the balance of 2025 and face significant premium increases and disruption in 2026. With limited prospects of multiple expansion and an unfavorable managed care catalyst calendar, investors are likely to be more sensitive to earnings revisions, which skew negatively for Part D- and ACA-sensitive stocks, such as Centene, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- Revised tax bill would speed up cuts to Medicaid, Bloomberg reports
- CMS to recover ‘uncollected overpayments’ amid Medicare audits
- CMS announces ‘significant expansion’ of Medicare Advantage audits
- Centene Holds Annual Meeting, Elects New Directors
- Proposal to cut Medicaid spending aims for GOP middle ground, WSJ says
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue